StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.82−0.10 (-1.69%)

Close on Nov 18, 2026Market cap $145.50KP/E –Yield –

AgomAb Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €48.88M, up 24.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€48.88M+24.3%
FY2024Dec 31, 2024€39.31M+49.4%
FY2023Dec 31, 2023€26.31M–

More AgomAb Therapeutics figures

See a number that looks wrong?